San Diego-based BioAtla, a company that produces cancer therapies, wrapped its initial public offering.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $1.48 |
|---|---|
| 52-week range | $1.14 - $4.02 |
| 50-day moving average | $1.92 |
| 200-day moving average | $2.14 |
| Wall St. target price | $10.67 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.46 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.5 from 2024-11-19
| 1 week (2024-11-14) | -12.28% |
|---|---|
| 1 month (2024-10-18) | -22.68% |
| 3 months (2024-08-20) | -20.63% |
| 6 months (2024-05-20) | -38.90% |
| 1 year (2023-11-20) | -10.18% |
|---|---|
| 2 years (2022-11-18) | -82.27% |
| 3 years (2021-11-19) | 27.37 |
| 5 years (2019-11-17) | N/A |
| Revenue TTM | $11 million |
|---|---|
| Gross profit TTM | $-79,347,000 |
| Return on assets TTM | -50.47% |
| Return on equity TTM | -139.06% |
| Profit margin | 0% |
| Book value | $0.48 |
| Market Capitalization | $82.7 million |
TTM: trailing 12 months
We're not expecting BioAtla to pay a dividend over the next 12 months.
You may also wish to consider:
Over the last 12 months, BioAtla's shares have ranged in value from as little as $1.14 up to $4.02. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BioAtla's is 1.018. This would suggest that BioAtla's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
To put BioAtla's beta into context you can compare it against those of similar companies.
BioAtla, Inc. , a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California. .
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.